SARS-CoV-2 PCR cycle threshold at hospital admission associated with patient mortality.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
09
2020
accepted:
16
12
2020
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cycle threshold (Ct) has been suggested as an approximate measure of initial viral burden. The utility of cycle threshold, at admission, as a predictor of disease severity has not been thoroughly investigated. We conducted a retrospective study of SARS-CoV-2 positive, hospitalized patients from 3/26/2020 to 8/5/2020 who had SARS-CoV-2 Ct data within 48 hours of admission (n = 1044). Only patients with complete survival data, discharged (n = 774) or died in hospital (n = 270), were included in our analysis. Laboratory, demographic, and clinical data were extracted from electronic medical records. Multivariable logistic regression was applied to examine the relationship of patient mortality with Ct values while adjusting for established risk factors. Ct was analyzed as continuous variable and subdivided into quartiles to better illustrate its relationship with outcome. Cumulative incidence curves were created to assess whether there was a survival difference in the setting of the competing risks of death versus patient discharge. Mean Ct at admission was higher for survivors (28.6, SD = 5.8) compared to non-survivors (24.8, SD = 6.0, P<0.001). In-hospital mortality significantly differed (p<0.05) by Ct quartile. After adjusting for age, gender, BMI, hypertension and diabetes, increased cycle threshold was associated with decreased odds of in-hospital mortality (0.91, CI 0.89-0.94, p<0.001). Compared to the 4th Quartile, patients with Ct values in the 1st Quartile (Ct <22.9) and 2nd Quartile (Ct 23.0-27.3) had an adjusted odds ratio of in-hospital mortality of 3.8 and 2.6 respectively (p<0.001). The discriminative ability of Ct to predict inpatient mortality was found to be limited, possessing an area under the curve (AUC) of 0.68 (CI 0.63-0.71). SARS-CoV-2 Ct was found to be an independent predictor of patient mortality. However, further study is needed on how to best clinically utilize such information given the result variation due to specimen quality, phase of disease, and the limited discriminative ability of the test.
Sections du résumé
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cycle threshold (Ct) has been suggested as an approximate measure of initial viral burden. The utility of cycle threshold, at admission, as a predictor of disease severity has not been thoroughly investigated.
METHODS AND FINDINGS
We conducted a retrospective study of SARS-CoV-2 positive, hospitalized patients from 3/26/2020 to 8/5/2020 who had SARS-CoV-2 Ct data within 48 hours of admission (n = 1044). Only patients with complete survival data, discharged (n = 774) or died in hospital (n = 270), were included in our analysis. Laboratory, demographic, and clinical data were extracted from electronic medical records. Multivariable logistic regression was applied to examine the relationship of patient mortality with Ct values while adjusting for established risk factors. Ct was analyzed as continuous variable and subdivided into quartiles to better illustrate its relationship with outcome. Cumulative incidence curves were created to assess whether there was a survival difference in the setting of the competing risks of death versus patient discharge. Mean Ct at admission was higher for survivors (28.6, SD = 5.8) compared to non-survivors (24.8, SD = 6.0, P<0.001). In-hospital mortality significantly differed (p<0.05) by Ct quartile. After adjusting for age, gender, BMI, hypertension and diabetes, increased cycle threshold was associated with decreased odds of in-hospital mortality (0.91, CI 0.89-0.94, p<0.001). Compared to the 4th Quartile, patients with Ct values in the 1st Quartile (Ct <22.9) and 2nd Quartile (Ct 23.0-27.3) had an adjusted odds ratio of in-hospital mortality of 3.8 and 2.6 respectively (p<0.001). The discriminative ability of Ct to predict inpatient mortality was found to be limited, possessing an area under the curve (AUC) of 0.68 (CI 0.63-0.71).
CONCLUSION
SARS-CoV-2 Ct was found to be an independent predictor of patient mortality. However, further study is needed on how to best clinically utilize such information given the result variation due to specimen quality, phase of disease, and the limited discriminative ability of the test.
Identifiants
pubmed: 33382805
doi: 10.1371/journal.pone.0244777
pii: PONE-D-20-27704
pmc: PMC7774957
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244777Déclaration de conflit d'intérêts
NO authors have competing interests.
Références
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Clin Infect Dis. 2017 Jun 15;64(suppl_3):S337-S346
pubmed: 28575373
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Clin Infect Dis. 2020 Nov 19;71(16):2158-2166
pubmed: 32445580
Diabetes Res Clin Pract. 2020 Apr;162:108142
pubmed: 32278764
J Infect. 2020 May;80(5):e1-e6
pubmed: 32171869
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Am J Phys Med Rehabil. 2020 Jul;99(7):583-585
pubmed: 32427600
Am J Pathol. 2020 Sep;190(9):1881-1887
pubmed: 32628931
Cell Biosci. 2020 Mar 16;10:40
pubmed: 32190290
BMJ. 2020 May 29;369:m1996
pubmed: 32471884
Jpn J Infect Dis. 2018 Jan 23;71(1):79-84
pubmed: 29093317
Clin Sci (Lond). 2005 Oct;109(4):365-79
pubmed: 16171460
Travel Med Infect Dis. 2020 May - Jun;35:101711
pubmed: 32360326
Clin Infect Dis. 2020 Jun 20;:
pubmed: 32562539
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32651238
J Thromb Thrombolysis. 2020 Oct;50(3):548-557
pubmed: 32524516
J Clin Virol. 2020 Jul;128:104412
pubmed: 32416600
Infect Dis Ther. 2020 Sep;9(3):573-586
pubmed: 32725536
Clin Infect Dis. 2020 Jun 30;:
pubmed: 32603425
Lancet Respir Med. 2020 Sep;8(9):e70
pubmed: 32771081
Clin Infect Dis. 2020 Nov 19;71(16):2252-2254
pubmed: 32435816
Am J Hypertens. 2020 Apr 29;33(5):373-374
pubmed: 32251498
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Ann Am Thorac Soc. 2020 Jul;17(7):790-794
pubmed: 32267164
Life Sci. 2020 Aug 1;254:117788
pubmed: 32475810
Int J Antimicrob Agents. 2020 May;55(5):105951
pubmed: 32234466
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32350048
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):303-310
pubmed: 32298981